Essayer OR - Gratuit

Why Holomedicine Is Rapidly Gaining Ground

BioSpectrum Asia

|

BioSpectrum Asia April 2022

Medical holography has emerged as one of the most promising applications in the medical industry. Holographic imaging technology is advancing healthcare, life sciences, biomedical research as well as medical training and education. Mixed Reality (MR) applications are gradually making a progressive impact on healthcare deliveries with precise quantitative measurement of human internal anatomy elements in 3D holograms geometries displayed in actual physical space. Holographic 3D technology renders medical professionals with advanced diagnostic capabilities and surgical planning, by allowing them to slice virtual tissue, organs, and other body parts at various angles. Holomedicne advances access to percutaneous procedures without invasive needle techniques. Surgeons across the world are now curious to explore medical holograms to enhance the efficiency of complex surgeries.

- Hithaishi C Bhaskar

Why Holomedicine Is Rapidly Gaining Ground

Typically, conventional 3D (3-Dimensional) imaging technologies are not able to create a truly accurate 3D rendition. Actually, these are 2D images gathered from MRI, CT scanner, ultrasound, and other devices, stitched together to create a rough 3D image. Furthermore, it is extremely laborious and time-consuming to create 3D visualisations from these 2D images. Treatment and diagnostic decisions based on these images are rather challenging, plus their accuracy is often questionable. As a solution to these challenges, novel revolutionary medical holography technology renders 2D images into 3D floating projections applying Mixed Reality (MR), a blend of physical and digital worlds, which unlocks natural and intuitive holograms through 3D interactions.

In contrast to AR/VR, in MR the real environment remains visible at all times and the holograms appear in the real space passing through a holographic device. This enables medical professionals to zoom in and zoom out the magnified 3D hologram of an organ/tissue under study. These visuals are indistinguishable in a conventional scanning procedure and thus holograms make treatments and surgeries a seamless effort with live explicit interactions.

Trends and opportunities in the medical holography market:

The clinical application of holography is thriving with the rising adoption of health-tech products in the life science and healthcare sector. The holography products can range from holography displays, holography microscopes, holography prints, holography software and devices, holographic headsets, and holoscopes.

PLUS D'HISTOIRES DE BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Translate

Share

-
+

Change font size